evenfolio

Consumer Services · NSE: ENTERO

Entero Healthcare Solutions

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
1,963.60−0.26%

Q2 FY27 earnings call · Guided by management

Call held 5 Nov 2026 · Read the filing on NSEFiling

23​%Consolidated revenue growth · FY 2027Agrawal · p. 4
₹1,000–0​CrMedTech revenue · MedTech · this yearAgrawal · Q&A · p. 11
5​%EBITDA margin · FY 2027Agrawal · p. 4
50​%EBITDA to operating cash flow conversion · this financial yearAgrawal · Q&A · p. 9
M.Cap
₹8,546Cr
P/E
61.3×
1Y return
+75.12%
From 52W high
−8.1%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue2,0871,571+32.9%1,940+7.6%
EBITDA11162+78.3%97+14.1%
EBITDA margin5.3%4.0%+135 bps5.0%+30 bps
PBTProfit before tax7845+75.7%67+16.8%
Net profit4632+44.1%38+19.3%
EPS (₹)10.457.25+44.1%8.76+19.3%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · FY2723%Company expects to beat FY27 guidance of about 23% consolidated revenue growth, excluding acquisitions
Revenue · MedTech · FY27Rs 1,000-— CrMedTech revenue to exceed Rs 1,000 crore this year
EBITDA margin · FY275%FY27 guidance: EBITDA margin of 5% and EBITDA to operating cash flow conversion of 50%

Full-year growth and margin expected to be better than earlier guidance

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 8
“But, you can be rest assured that it would be better than what we had guided before, both on the growth and on the margin.”

Company will do better than guided but gives no new revenue guidance

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 5
“I am not specifically giving a new guidance right now on the call, but I can very confidently say that we will do better than what we have guided.”

Organic growth without acquisitions next year described as 'our endeavor'

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 15
“Yes, that will be our endeavor for sure. Organically also, there are many opportunities, not that all the opportunities lie in only the inorganic realm.”

More figures from the call

MedTech · Segments
15​%MedTech share of revenue
“MedTech, as we have guided before, it is in a range of 15%+ of our total revenues.”
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&Ap. 6
Company · Debt and working capital
2​×Net debt to EBITDA cap
“The board, internally, we have this mandate that we will not exceed 2x net debt to EBITDA ratio.”
Prabhat Agrawal · Managing Director and Chief Executive Officerp. 10

In short

  1. 01Management expects to beat its FY27 guidance of about 23% revenue growth and 5% EBITDA margin.
  2. 02The 50% EBITDA-to-operating-cash-flow conversion guidance for FY27 is kept.
  3. 03Q2 revenue grew 32.9% to Rs 2,087 crore; EBITDA margin rose 135 bps to 5.3%.
  4. 04Net working capital days were 64 due to delayed Maharashtra government payments, since received.
  5. 05MedTech is 15%+ of revenue and expected to exceed Rs 1,000 crore this year.
  6. 06Management is evaluating acquisitions, none below Rs 100 crore, and hopes to close one this year.
  7. 07Trade margin caps and MRP cuts are not expected to affect margins; notified molecules are 2% of sales.
  8. 08A subsidiary customer default led to a provision in Other Expenses in Q2.

Segments

MedTech: Company expanding addressable market across healthcare products, particularly MedTech

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“We are progressively expanding our addressable market by building capabilities across the broader healthcare products ecosystem, particularly in MedTech.”

MedTech: MedTech still has product categories the company does not yet handle

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 15
“MedTech, we still have a lot of other categories left. Pharma, more or less, we have covered quite a bit. But in MedTech, we still have other product categories still which we are not doing today.”

Calendarisation boost from past acquisitions to taper in Q3 and more in Q4

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 7
“Yes, certainly the calendarisation impact will definitely go down until and unless we announce new acquisitions, because it is going to taper off partly in quarter three and more so in quarter four.”

Demand

Indian healthcare product market expected to keep growing at double digits

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“The Indian healthcare product market remains largely fragmented and is expected to continue growing at a healthy double-digit pace.”

Company says it continues to gain market share ahead of industry growth

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
“We continue to gain market share, outpacing industry growth.”

Organic growth from more customers, higher wallet share and new product categories

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 10
“It includes expansion in customer base, it includes improvement in wallet share from the customers, it includes new product categories, growth coming from new product categories.”

H1 reach: over 92,200 retail and 2,900 hospital customers in about 500 districts

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“In H1, we served over 92,200 retail customers and more than 2,900 hospital customers, spread in approximately 500 districts in more than 20 states and union territories”

Recent pharma market growth mostly from volume; no view on how long it lasts

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 14
“Most of this growth has come from volume growth rather than pricing or new product introduction. So how long is this sustainable, those kinds of growth rates? I don't have any particular view on that.”

Margins and costs

Q2 gross margin up 126 bps to 11.5%; EBITDA margin up 135 bps to 5.3%; EBITDA up 78%

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
“Gross margin expanded 126 basis points year-on-year to 11.5%, and EBITDA margin expanded 135 basis points to 5.3%, and EBITDA grew by 78% year-on-year.”

Margin gains from procurement scale, more MedTech revenue and exit from low-margin accounts

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
“Margin expansion was driven by three levers: scale-led procurement economies, a growing share of revenue from MedTech business, and the deliberate exit from certain low-margin accounts.”

H1 gross profit Rs 461 crore, gross margin 11.5%

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“Gross profit was INR461 crores, with a margin at 11.5%.”

Margins depend on value added, such as demand generation, more than on product

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 6
“So, the margin is more dependent on the value- add that you have provided rather than by the specific product that you are selling.”

Debt and working capital

Net working capital days at 64 due to delayed government receivables in Maharashtra

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“Net working capital days were at 64 days due to timing in trade receivables on certain government contracts. This was on account of funds being reallocated due to drought situation in Maharashtra.”

Delayed collection received in November; adjusted NWC days would be 61

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“I would like to mention that collection has been received in November, and adjusting for that, NWC days would have been 61 days, which is similar to the previous quarter.”

Delayed Maharashtra government payment received in November was about Rs 55 crore

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 15
“I think it was around INR55 crore.”

H1 operating cash outflow of Rs 46.5 crore, hit by Maharashtra fund reallocation

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“Operating cash flow was negative INR46.5 crores. As I mentioned before, NWC days and consequently OCF were impacted on account of reallocation of funds by the government due to the drought situation in Maharashtra.”

H1 NWC days improved to 66 from 68; H1 EBITDA margin 5.2%

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“EBITDA margin in first of the year was 5.2%. NWC days improved to 66 compared to 68 in the comparable period last year.”

Acquisitions and new business

Acquisition opportunities being evaluated that could close this year

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 8
“No, we are evaluating some opportunities that can be closed in this year itself.”

Large acquisitions available in pharma and MedTech; hopeful of a deal this year

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 12
“We are evaluating opportunities there. It is not that we are not engaging with anyone or we are not looking at it. We are evaluating, and I am hopeful something will happen this year.”

Not looking at acquisitions below Rs 100 crore

₹100–0​Cr
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 12
“We are not looking at something which is lower than INR100 crore.”

Acquisition targets: portfolio expansion into new product categories or new geographies

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 8
“Most of the opportunities that we are evaluating are in the space either which leads to a portfolio expansion for us or in product categories that we are not dealing in today or related to new geography that we don't have much presence today.”

Management favours product expansion in acquisitions

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 9
“Generally, we are more excited by product expansion. I can just tell you that.”

One-offs

Government contract payment delay to be treated as one-off

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 13
“We should take that as one-off, and if we account for that, then, the NWC days or working capital days would have been the same as the previous quarter.”

Customer of a subsidiary defaulted; entire amount provided in Other Expenses

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 9
“Entire amount, as we said in that note, has been provided in, regarding that receivable in our books in Other Expenses line.”

Company has legal rights to recover defaulted subsidiary receivable

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 9
“Basically, the issue is about a customer default from one of our subsidiaries, a customer of one of our subsidiaries. And we have all the legal rights to go for recovery.”

Part of the default was provided earlier; a significant part in Q2

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 9
“Not all of it. Partial part of it, because part of it was already provided before, so it is part of our opening provision balance. But yes, a significant part of it was provided in this quarter itself.”

Q2 margin would have been higher without the subsidiary receivable provision

Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 7
“Yes, the margin would have been higher, if we had not provided the amount in Q2.”

Risks

MRP revisions and trade margin cap not likely to affect company margins

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 5
“Whatever MRP revisions happen, or whatever new products are being brought into the trade margin cap, okay, it is not likely to impact our margin profile as such. The reason being, we were not making those kinds of extra margins.”

137 molecules notified by NPPA are only 2% of company sales

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 11
“But when I look at my sales, these 137 molecules that has been as of now notified by NPPA, that those molecules total sales in our portfolio is only 2% as of now.”

Oncology MRP cuts expected to fall mostly on hospitals, partly manufacturers, not distributors

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 14
“But we don't see any major or any impact coming to a distributor, because distributor anyway was not making a lot of margins in this.”

Distributor margin percentage did not change in 2019 or under past DPCO and MRP cuts

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 11
“Now, coming to the second one, the margin percentage did not change. It did not change in 2019. It has not changed ever from whenever the DPCO or any MRP reduction happened.”

Unknown whether manufacturers will cut prices later; little impact seen for now

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 11
“But, I do not know if some of it will be passed back to the company and they reduce the pricing later on. But as of now, I do not see much of an impact coming from that.”

Other

Q2 consolidated revenue grew 32.9% to Rs 2,087 crore

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
“Consolidated revenues grew by 32.9% to INR2,087 crores.”

Q2 organic growth was 18.2%, or 20% like-for-like

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
“Organic growth was strong at 18.2% and 20% on a like-for-like basis.”

Q2 profit after tax Rs 61 crore, up 66%, PAT margin 2.9%

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“Profit after tax for the quarter was INR61 crores, up 66% year-on-year, with a PAT margin of 2.9%.”

Q2 profit attributable to owners Rs 46 crore, up 44%

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“Profit after tax attributable to owners was INR46 crores, up 44% year-on-year.”

Q2 ROCE 22.0% and ROE 22.4%

Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
“ROCE and ROE were 22.0% and 22.4%, respectively.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools